Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer.

Cancer treatment and research communications - 1 Jan 2025

Levine Kevin M, Uy Natalie F, Gooley Ted A, Voutsinas Jenna, Tratt Micah, Eaton Keith D, Santana-Davila Rafael, Berger Alice H, Baik Christina S

Abstract excerpt

Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Although retreatment with earlier-generation EGFR tyrosine kinase inhibitors has been studied, data on osimertinib rechallenge are limited. We conducted a single institution retrospective analysis of patients with EGFR-mutated NSCLC who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 41175446
DOI: 10.1016/j.ctarc.2025.101026
PMCID: PMC12758605

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer.PMID 41175446Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.Semantic proximity Read ↗

Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib.Semantic proximity Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.Semantic proximity Read ↗

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.Semantic proximity Read ↗

Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.